Health care; creating the Oklahoma Rebate Pass-Through and Pharmacy Benefits Manager Meaningful Transparency Act of 2025; definitions; requirements; effective date.
HB2817 creates the “Oklahoma Rebate Pass-Through and Pharmacy Benefits Manager Meaningful Transparency Act of 2025” and expands Oklahoma’s existing pharmacy benefit manager (PBM) and prescription drug rebate rules. The bill requires that an enrollee’s cost sharing for a prescription drug be calculated at the point of sale using a price reduced by at least 85% of rebates received, or expected to be received, for that drug. It also authorizes the Insurance Commissioner to impose administrative penalties for violations and preserves the ability of PBMs and insurers to pass through more than the minimum required amount to consumers.
The bill also amends Oklahoma’s PBM statutes to broaden definitions, strengthen disclosure and audit obligations, and add new licensing requirements. It requires PBMs to provide more information to the Attorney General, insurers, self-funded employers, and unions, including quarterly reporting on rebates, pass-through amounts, and pharmacy payments. It further revises formulary and pharmacy network rules, including conflict-of-interest standards for pharmacy and therapeutics committees, transparency requirements for formulary decisions, and restrictions on spread pricing and certain pharmacy fees. The bill also states that rebate information and related proprietary data are trade secrets and not public records.
In practical terms, the measure would affect insurers, PBMs, pharmacies, employer-sponsored plans, and state regulators by changing how prescription drug rebates are reflected in patient cost sharing and by increasing oversight of PBM business practices. It would amend multiple sections of Titles 36 and 59 of the Oklahoma Statutes, including definitions, compliance duties, formulary governance, and PBM licensure and enforcement provisions. The bill appears designed to shift more rebate value to consumers at the pharmacy counter while also preserving confidentiality around rebate amounts and related commercial information.
The general sentiment reflected by the bill text is strongly pro-transparency and consumer cost relief, with a clear policy goal of limiting PBM practices that may keep rebates from lowering out-of-pocket drug costs. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of debate, but the structure of the bill suggests support for tighter regulation of PBMs and stronger disclosure to state officials and plan sponsors. At the same time, the bill anticipates resistance by repeatedly protecting rebate and pricing data as confidential and by limiting state regulation to what is permissible under applicable law.
The main points of contention likely involve the 85% rebate pass-through requirement, the scope of reporting and audit access, and the confidentiality provisions shielding rebate data from public disclosure. PBMs and insurers may object to the administrative burden, enforcement exposure, and limits on how rebate information can be used or disclosed, while pharmacies, consumers, and transparency advocates would likely favor the bill’s restrictions on spread pricing, network fees, and opaque rebate retention. The bill’s balance between mandatory pass-through and trade-secret protections suggests an attempt to address both consumer pricing concerns and industry concerns about proprietary information.
HB2817 would amend and add provisions in Titles 36 and 59 governing PBMs, insurers, pharmacy networks, and formulary management. It would require point-of-sale cost sharing to reflect at least 85% of rebates, expand reporting and audit rights, impose new licensing application disclosures and enforcement tools, and tighten rules on spread pricing, pharmacy fees, and formulary committee conflicts. It also declares rebate-related information confidential and not subject to the Oklahoma Open Records Act, affecting insurers, PBMs, pharmacies, employers, and state agencies involved in prescription drug benefit administration.
The bill’s overall tone is reform-oriented and consumer-protective, emphasizing rebate pass-through, transparency, and oversight of PBM practices. No committee discussion or vote record is provided, so there is no direct evidence of bipartisan support or opposition, but the bill’s detailed regulatory approach suggests it is intended to respond to concerns about drug pricing and PBM opacity. Its confidentiality provisions and limits on state regulation indicate an effort to temper that reform with protections for proprietary business information.
Likely areas of contention include the mandatory 85% rebate pass-through standard, the breadth of quarterly reporting and audit access, and the extent to which PBMs and insurers must disclose rebate and pricing information to regulators and plan sponsors. PBMs and insurers would likely resist provisions they view as burdensome or commercially sensitive, while consumer advocates, pharmacies, and transparency proponents would likely support stronger pass-through requirements and restrictions on spread pricing and network fees. The bill’s explicit trade-secret protections suggest lawmakers anticipated pushback over public disclosure of rebate data.